F8 and hemophilia A: Majority of the participants included in the study were above the age of 18 years, had spontaneous bleeding episodes of more than 20, were mostly moderate cases of hemophilia A, and did not have FVIII inhibitors or a record of ITI therapy or prior use of bypassing agents, which was anticipated and consistent with demographic information on the hemophilia A population in previous studies [15, 25].